Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;46(1-3):192-205.
doi: 10.1007/s12026-009-8121-x.

Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms

Wasif Riaz  1 , Francisco J Hernandez-Ilizaliturri, Myron S Czuczman
Affiliations
Review

Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms

Wasif Riaz et al. Immunol Res. 2010 Mar.

Abstract

Rituximab is a chimeric monoclonal anti-CD20 antibody and was the first monoclonal antibody (mAb) therapy approved by FDA (Food and Drug Administration) for the treatment of B-cell lymphoma. It has revolutionized the treatment of patients with CD20-positive non-Hodgkin's lymphoma and CLL. Rituximab is currently being used in virtually all patients with B-cell lymphomas either alone or in combination with chemotherapy. Despite its excellent safety and efficacy profile, only a small portion of B-cell lymphoma patients treated with rituximab as a single agent have sustained complete remissions. Combining rituximab with standard chemotherapy regimens is associated with higher response rates, and improved survival in a subset of patients. Unfortunately, a significant percentage of patients who initially respond to rituximab eventually relapse, and there are patients that demonstrate intrinsic resistance to initial therapy. In the last decade, ongoing scientific research has led to a better understanding of rituximab-associated cytotoxic mechanisms against lymphoma target cells. Scientific efforts are increasingly being focused in developing new strategies to improve mAb activity. Various strategies include the following: combining rituximab with different biologic agents (e.g. cytokines, immunomodulatory drugs); developing novel antibody constructs (including bi-specific antibodies); and/or inhibiting signaling pathways associated with lymphomagenesis and immuno-chemotherapy resistance. In this review article, we will provide an overview of various rituximab-associated cytotoxic mechanisms and novel strategies to improve mAb activity against B-cell lymphoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nat Med. 2000 Apr;6(4):443-6 - PubMed
    1. Arthritis Rheum. 2003 Feb;48(2):455-9 - PubMed
    1. J Immunol. 2006 Jul 1;177(1):362-71 - PubMed
    1. Haematologica. 2007 Jul;92(7):998-9 - PubMed
    1. Blood Cells Mol Dis. 2000 Apr;26(2):133-43 - PubMed

MeSH terms

LinkOut - more resources

-